Lehigh Valley Injectable Medicine and Device Facility

Lilly's planned $3.5 billion Lehigh Valley injectable-medicine and device manufacturing facility will create 850 high-value permanent jobs and target operations by 2031. The approximately 2,000 construction jobs and Lilly's broader national manufacturing commitment are excluded from this project-level total.

Investment
$3.50B
Permanent jobs announced
850
Status
Planning
Expected opening
2031
Why this project qualifies

With $3.5 billion in facility-specific investment and 850 permanent operating jobs announced, this project clears both of AFT's qualifying thresholds ($100 million in facility-specific investment OR 100 permanent operating jobs). This project also meets AFT's primary-source verification and physical U.S. manufacturing-footprint requirements.

View full methodology →
Why it matters

The pharmaceuticals context.

Pharmaceutical manufacturers are committing billions to new U.S. production capacity for active ingredients, injectable medicines, biologics and other high-demand treatments. North Carolina and Indiana remain major centers of investment, while new facilities are being planned across the South. The current project pipeline includes both large greenfield campuses and major expansions of established production sites.

Project record

At a glance

Company
Eli Lilly
Industry
Pharmaceuticals
Location
Upper Macungie Township, Pennsylvania
Investment
$3.50B
Permanent jobs announced
850
Status
Planning
Announced
Jan 30, 2026
Expected opening
2031
Added to tracker
Aug 30, 2026
Sources

Official references

Related

Other projects to know

Back to the tracker/projects/eli-lilly-lehigh-valley